JPRN-jRCT2080221082未知3 期
Open Phase III Study of ME2080 in Patients with Dravet Syndrome
Meiji Seika Pharma Co., Ltd. (formerly MEIJI SEIKA KAISHA Co., LTD.)0 个研究点目标入组 25 人开始时间: 2010年4月28日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 1age old 至 <= 30age old（—）
- 性别
- All
入选标准
- •1)Seizure type: Patients who have an epileptic seizure at least 4 times per month
- •2)Inpatient/outpatient: Either inpatient or outpatient
- •3)Body weight: 5 kg or more
- •4)Concomitant antiepilepsy drugs: Patients receiving treatment with the following combinations of antiepilepsy drugs:
- •- Clobazam e + Sodium valproat [+ Bromide]
- •5)Consent of patient: Patients whose written consent for participation in the study is provided by themselves or their delegates.
- •When subjects complete the 12-week evaluation period, and patients themselves or their delegates hope continued administration, they will shift to the long-term administration phase.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Long Term Extension Study of E2080 in Patients with Lennox-GastautSyndromeEUCTR2016-004953-34-Outside-EU/EEAEisai Co, Ltd.54
进行中（未招募）
3 期
Phase III Clinigal Study of ME3208 in Patients with cGVHDChronic graft versus host diseaseJPRN-jRCT2011210041Kijima Koji20
招募中
2 期
Study of NM8074 in Adult PNH PatientsCTRI/2023/02/049717ovelMed Therapeutics
尚未招募
2 期
Treatment of Chronic aHUS with NM8074CTRI/2023/10/058601ovelMed Therapeutics
进行中（未招募）
3 期
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC), Unresponsive to Bacillus-Calmette-Guerin (BCG)on Muscular Invasive Bladder CancerJPRN-jRCT2043210017Shimizu Yoshitaka110